Sugi Predict

Sugi Predict / Compounds / SCHEMBL6306378

SCHEMBL6306378

SCHEMBL6306378

CCn1c(=O)[nH]c2cc(C(=O)OC)ccc2c1=O

nearest known ligand 0.77

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.77
▸ MEN1 O00255 3/20 0.77
▸ ALDH1A1 P00352 14/20 0.76
▸ KDM4E B2RXH2 12/20 0.76
▸ GAA P10253 10/20 0.76
▸ HPGD P15428 9/20 0.76
▸ GLA P06280 5/20 0.76
▸ HSD17B10 Q99714 5/20 0.76
▸ HTT P42858 3/20 0.76
▸ PKM P14618 2/20 0.76
▸ SMN1; SMN2 Q16637 2/20 0.64
▸ TDP1 Q9NUW8 2/20 0.60
▸ MAPT P10636 2/20 0.59
▸ TP53 P04637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30414309 1.00 KMT2A (0.77) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL27202769 0.88 ALDH1A1 (0.63) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL27202753 0.87 KMT2A (0.70) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL25236133 0.85 ALDH1A1 (0.69) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL2118623 0.85 ALDH1A1 (0.69) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL27202845 0.85 ALDH1A1 (0.74) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL4252121 0.83 MAPT (0.68) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL2117984 0.82 ALDH1A1 (0.69) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL30183620 0.82 ALDH1A1 (0.69) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL4253579 0.82 GAA (0.65) KMT2AMEN1ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163022-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. 2025-05-22 — — US disclosed
EP-4452963-A1 PARP1 INHIBITORS Synnovation Therapeutics, Inc. (US) 2024-10-30 — — EP disclosed
US-20240208969-A1 SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) 2024-06-27 — — US disclosed
CN-117653636-B Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound 上海瑛派药业有限公司 2024-04-26 — — CN disclosed
US-20240132449-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. 2024-04-25 — — US disclosed
CN-117653636-A Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound 上海瑛派药业有限公司 2024-03-08 — — CN disclosed
WO-2024050370-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. (US) 2024-03-07 — — WO disclosed
CN-116783181-A Substituted fused bicyclic compounds as PARP inhibitors and use thereof 上海瑛派药业有限公司 2023-09-19 — — CN disclosed
WO-2023122140-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-06-29 — — WO disclosed
WO-2023122140-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-06-29 — — WO disclosed
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 — — US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 — — US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 — — US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 — — US disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208969-A1 SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF PARP1, PARP3, PARP11 KMT2A 1411/4885MEN1 2704/4885ALDH1A1 217/4885
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 KMT2A 1218/4885MEN1 4378/4885ALDH1A1 570/4885
US-20250163022-A1 PARP1 INHIBITORS PARP1, PARP11, PARP12 KMT2A 740/4885MEN1 2993/4885ALDH1A1 2238/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM KMT2A 1587/4885MEN1 4834/4885ALDH1A1 1067/4885
US-20240132449-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF PARP1, PARP11, PARP12 KMT2A 1465/4885MEN1 2494/4885ALDH1A1 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.